---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-035613"
form_type: "8-K"
ticker: "NKTX"
cik: "0001787400"
company_name: "Nkarta, Inc."
filed_at: "2024-03-25T23:59:59+00:00"
generated_at: "2026-06-04T08:35:23.868364+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nkarta shares NKX019 B-cell reconstitution and PK data from Phase 1 NHL trial

## Summary
- After NKX019 treatment, circulating CD19+ cells rapidly depleted; B-cell repertoire recovered with naïve, non-class-switched isotypes in 5 patients at 3 months.
- No patients had prior CAR T therapy; recovery pattern consistent with CAR T experience in autoimmune disease.
- Preliminary PK data from 2 patients with DLBCL show similar NKX019 exposure after Flu/Cy vs Cy alone lymphodepletion.
- B-cell recovery confirmed by single-cell RNA profiling, showing naïve and intermediate B cell transcriptome profiles.
- Company highlights potential of NKX019 for autoimmune diseases such as lupus nephritis.

## SEC filing metadata
- accession: 0000950170-24-035613
- form_type: 8-K
- ticker: NKTX
- cik: 0001787400
- company_name: Nkarta, Inc.
- filed_at: 2024-03-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787400/000095017024035613/0000950170-24-035613-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787400/000095017024035613/nktx-20240325.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-035613
- JSON: https://secwatch.observer/filing/0000950170-24-035613.json
- Plain text: https://secwatch.observer/filing/0000950170-24-035613.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.